Switching to DOR/3TC/TDF led to more favorable changes in cardiovascular (SCORE-2) and metabolic (METS-IR) risk scores than DTG/3TC or BIC/FTC/TAF in an Italian cohort.
Does switching to DOR/3TC/TDF improve SCORE-2 and METS-IR compared to DTG/3TC and BIC/FTC/TAF in a multicenter Italian cohort?
Switching to DOR/3TC/TDF is associated with more favorable changes in cardiovascular and metabolic risk scores compared to other common antiretroviral regimens.
Absolute Event Rate: 0% vs 0%
We found that switching to DOR/3TC/TDF was associated with more favorable changes in SCORE-2 and METS-IR compared to DTG/3TC and BIC/FTC/TAF.
Zini et al. (Mon,) reported a other. Switching to DOR/3TC/TDF led to more favorable changes in cardiovascular (SCORE-2) and metabolic (METS-IR) risk scores than DTG/3TC or BIC/FTC/TAF in an Italian cohort.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: